Anixa Biosciences (NASDAQ:ANIX) Upgraded to “Hold” at Wall Street Zen

Anixa Biosciences (NASDAQ:ANIX – Get Free Report) was upgraded by investment analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report released on Saturday, Wall Street Zen reports.

A number of other equities research analysts have also issued reports on the stock. Weiss Ratings raised shares of Anixa Biosciences from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, September 17th. HC Wainwright lowered their target price on shares of Anixa Biosciences from $7.00 to $6.00 and set a “buy” rating on the stock in a report on Tuesday, September 22nd. Citigroup restated a “buy” rating on shares of Anixa Biosciences in a research report on Tuesday, October 6th. Finally, Zacks Research cut shares of Anixa Biosciences from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, August 19th. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Anixa Biosciences presently has a consensus rating of “Hold” and an average target price of $8.00.

View Our Latest Stock Analysis on ANIX

Anixa Biosciences Stock Down 6.2%

NASDAQ ANIX opened at $2.44 on Friday. The firm has a market cap of $84.81 million, a price-to-earnings ratio of -7.62 and a beta of 0.47. The business has a 50-day moving average price of $2.85 and a 200-day moving average price of $2.95. Anixa Biosciences has a twelve month low of $2.32 and a twelve month high of $5.46.

Anixa Biosciences (NASDAQ:ANIX – Get Free Report) last released its earnings results on Wednesday, September 9th. The company reported ($0.08) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.08). Research analysts expect that Anixa Biosciences will post -0.31 EPS for the current fiscal year.

Insider Buying and Selling

In other news, Director Lewis Titterton, Jr. purchased 49,036 shares of the business’s stock in a transaction on Wednesday, September 23rd. The stock was acquired at an average price of $2.69 per share, for a total transaction of $131,906.84. Following the acquisition, the director directly owned 1,046,003 shares of the company’s stock, valued at $2,813,748.07. This represents a 4.92% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders purchased 105,536 shares of company stock worth $291,587 over the last three months. 26.40% of the stock is currently owned by corporate insiders.

Institutional Trading of Anixa Biosciences

Several hedge funds have recently modified their holdings of ANIX. Renaissance Technologies LLC boosted its position in shares of Anixa Biosciences by 13.6% during the 1st quarter. Renaissance Technologies LLC now owns 61,173 shares of the company’s stock valued at $158,000 after acquiring an additional 7,300 shares during the last quarter. CoreCap Advisors LLC increased its position in Anixa Biosciences by 19.2% in the third quarter. CoreCap Advisors LLC now owns 62,020 shares of the company’s stock worth $182,000 after purchasing an additional 10,000 shares during the last quarter. Sanctuary Advisors LLC bought a new stake in Anixa Biosciences in the second quarter worth $29,000. Northwestern Mutual Wealth Management Co. purchased a new stake in Anixa Biosciences during the second quarter valued at $29,000. Finally, Integrated Wealth Concepts LLC purchased a new stake in Anixa Biosciences during the second quarter valued at $30,000. 29.13% of the stock is owned by hedge funds and other institutional investors.

Anixa Biosciences Company Profile

(Get Free Report)

Anixa Biosciences, Inc. is a U.S.-based biotechnology company focused on developing cancer immunotherapies. Its research programs include a CAR T-cell therapy designed to target ovarian cancer and cancer vaccine candidates developed with research partners. The company’s ovarian cancer program uses T cells engineered to recognize follicle-stimulating hormone receptors on cancer cells and is being developed in collaboration with Moffitt Cancer Center. Anixa is also working with Cleveland Clinic on a breast cancer vaccine program intended to stimulate an immune response against cancer-related targets.

Further Reading

Analyst Recommendations for Anixa Biosciences (NASDAQ:ANIX)

Receive News & Ratings for Anixa Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anixa Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.